Related references
Note: Only part of the references are listed.DNA methylation profiling identifies epigenetic differences between early versus late stages of diabetic chronic kidney disease
Ashani Lecamwasam et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2021)
The global burden of chronic kidney disease
Paul Cockwell et al.
LANCET (2020)
Identification of Potential Biomarkers of Chronic Kidney Disease in Individuals with Diabetes: Protocol for a Cross-sectional Observational Study
Ashani R. Lecamwasam et al.
JMIR RESEARCH PROTOCOLS (2020)
Ketoacid Analogues Supplementation in Chronic Kidney Disease and Future Perspectives
Laetitia Koppe et al.
NUTRIENTS (2019)
Disorders of Lipid Metabolism in Chronic Kidney Disease
Mustafa C. Bulbul et al.
BLOOD PURIFICATION (2018)
Lipid management in patients with chronic kidney disease
Charles J. Ferro et al.
NATURE REVIEWS NEPHROLOGY (2018)
Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
F. E. Dewey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Metabolomics of Chronic Kidney Disease Progression: A Case-Control Analysis in the Chronic Renal Insufficiency Cohort Study
Eugene P. Rhee et al.
AMERICAN JOURNAL OF NEPHROLOGY (2016)
Metabolomics in Diabetic Kidney Disease: Unraveling the Biochemistry of a Silent Killer
Manjula Darshi et al.
AMERICAN JOURNAL OF NEPHROLOGY (2016)
Serum Trimethylamine-N-Oxide Is Strongly Related to Renal Function and Predicts Outcome in Chronic Kidney Disease
Catharina Missailidis et al.
PLOS ONE (2016)
Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease
Peter P. Toth
VASCULAR HEALTH AND RISK MANAGEMENT (2016)
Is There a Role for Ketoacid Supplements in the Management of CKD?
Anuja P. Shah et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2015)
Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Cardiovascular Epidemiology and Genetics
Pasi Soininen et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2015)
Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Cardiovascular Epidemiology and Genetics
Pasi Soininen et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2015)
Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney disease
Nosratola D. Vaziri
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2014)
Chronic Renal Disease and Risk of Cardiovascular Morbidity-Mortality
Antonio Santoro et al.
KIDNEY & BLOOD PRESSURE RESEARCH (2014)
KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient
Christoph Wanner et al.
KIDNEY INTERNATIONAL (2014)
Role of HDL Dysfunction in End-Stage Renal Disease: A Double-Edged Sword
Hamid Moradi et al.
JOURNAL OF RENAL NUTRITION (2013)
The Human Urine Metabolome
Souhaila Bouatra et al.
PLOS ONE (2013)
Summary of Recommendation Statements
Adeera Levin et al.
KIDNEY INTERNATIONAL SUPPLEMENTS (2013)
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
M. John Chapman et al.
EUROPEAN HEART JOURNAL (2011)
The global burden of diabetes and its complications: an emerging pandemic
Susan van Dieren et al.
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION (2010)
High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism
Pasi Soininen et al.
ANALYST (2009)
Persistent Inflammation as a Catalyst for Other Risk Factors in Chronic Kidney Disease: A Hypothesis Proposal
Juan Jesus Carrero et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Chronic kidney disease delays VLDL-apoB-100 particle catabolism: potential role of apolipoprotein C-III
Doris T. Chan et al.
JOURNAL OF LIPID RESEARCH (2009)
Risk stratification of apolipoprotein B, apolipoprotein A1, and apolipoprotein B/AI ratio on the prevalence of the metabolic syndrome: the ATTICA study
Christos Pitsavos et al.
ANGIOLOGY (2008)
Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study
Matthew J. McQueen et al.
LANCET (2008)
The unique character of cardiovascular disease in chronic kidney disease and its implications for treatment with lipid-lowering drugs
Joseph Nogueira et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
Lipoprotein metabolism and lipid management in chronic kidney disease
Bonnie C. H. Kwan et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study
S Yusuf et al.
LANCET (2004)
High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study
G Walldius et al.
LANCET (2001)
The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus
CT Valmadrid et al.
ARCHIVES OF INTERNAL MEDICINE (2000)
Share Paper
